Klein Lawrence Otto 4

What Happened

• Lawrence Otto Klein (listed as Klein Lawrence Otto), CEO of Oruka Therapeutics, received equity awards on 2026-01-23. The filing shows an acquisition of 76,700 shares at $0.00 and an acquisition of 306,700 derivative securities at $0.00, for a total of 383,400 shares/derivative instruments. No cash was paid; these are grants/awards rather than market purchases or sales.

Key Details

• Transaction date: 2026-01-23. Report filed the same day.
• Transaction type/code: A (grant/award or other acquisition); one line reported as derivative acquisition.
• Price: $0.00 for both the 76,700 and 306,700 items (total = 383,400).
• Vesting/terms (from filing footnotes):
  • Footnote F1: The 76,700-share grant vests 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or the immediately preceding trading day if not a trading day).
  • Footnote F2: The 306,700 derivative/security vests at 1/48 of the underlying shares monthly beginning January 1, 2026.
• Shares owned after transaction: not specified in the reported lines of this filing.
• Timeliness: Filed on the same date as the reported transactions (no late filing indicated).

Context

• These entries are awards/vesting schedules, not open-market purchases or sales, and therefore are typical compensation-related grants rather than immediate bullish purchases or disposition signals.
• The derivative grant vests monthly (per F2); there is no indication in this filing that any shares were sold immediately (no cashless exercise or sale reported).
• For retail investors, note that such grants dilute share count over time when vested shares are issued, but they do not by themselves indicate the insider is buying or selling company stock.